Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>M Stanley Ratings, TPs on CN Biotechs (Table)
Recommend 25 Positive 26 Negative 17 |
||||
|
||||
|
Shares | Ratings | Target prices (HK$) KEYMED BIO-B(02162.HK) | Overweight | 93.5 -> 97 INNOVENT BIO(01801.HK) | Overweight | 130 -> 135 LEADS BIOLABS-B(09887.HK) | Equalweight | 59 -> 62 HUTCHMED(00013.HK) | Underweight -> Equalweight | 21.4 -> 21.3 REMEGEN(09995.HK) | Equalweight | 89 -> 98 INNOCARE(09969.HK) | Equalweight -> Overweight | 19.6 -> 17 DUALITYBIO-B(09606.HK) | Overweight | 493 ABBISKO-B(02256.HK) | Overweight | 22 ZAI LAB(09688.HK) | Overweight | 19 VISEN PHARMA-B(02561.HK) | Overweight | 50 EVEREST MED(01952.HK) | Equalweight | 40 Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
